Please login to the form below

Not currently logged in

Pharmaceutical Market Europe - December 2014

PME December 2014As 2014 draws to a close it’s certainly been an interesting years for the industry, with the resurgence of M&A deals providing just one headline-grabbing example of continued pharma shifts.

But rather than look back for PME’s last issue of 2014 we wanted to give our readers a preview of what 2015 will bring.

High on the industry’s agenda will be clinical transparency when, from January, the EMA starts publishing clinical study reports for new medicine applications. Ahead of this milestone we spoke to Guido Rasi, in one of his last interviews before his appointment as EMA executive director was annulled, GSK’s Patrick  Vallance, MEP Glenis Willmott and Bad Pharma author Ben Goldacre and asked will 2015 usher in a new era for the industry?

In the increasingly competitive orphan drugs market we looked at the products expected to be the rising stars over the next five years and we got an inside look at NICE’s new process for assessing drugs to treat ultra-rare conditions.

We also heard from Patrick Vink, general manager of international business for Cubist, in a timely interview that took place just before his company was acquired for $8.4bn by Merck & Co.

The December issue is available to view online now, but if you don't currently receive PME on a regular basis you can subscribe to the print or digital edition - or keep up with pharma news on a more regular basis via our PMLiVE Daily or Weekly email newsletters.

Register here to receive email notification of future digital editions of PME or contact the subscriptions department to enquire about receiving a print copy of the magazine. More PMLiVE digital editions can be found here.

PME is also available to download as an app for iPhone and iPad

Please note: Some older digital editions may no longer be accessible while we transition to a new digital edition system and app -

COVID-19 Updates and Daily News

Featured jobs


Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...